Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Zurzuvae was not approved as a treatment for major depressive disorder, as the two Cambridge drugmakers had been hoping. Biogen and Sage decided last year not pursue further development of the ...

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, with a market cap of $21.9 billion, is a leading biotechnology company specializing in developing and delivering innovative therapies.

The Cambridge, Massachusetts-based biotech added that its board of directors, along with its independent financial and legal advisors, will evaluate Biogen’s (NASDAQ:BIIB) bid and decide on the ...

Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...

The proposal values Sage at around $442 million. A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, according to the filing.

CAMBRIDGE, Mass., January 10, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) ("The Company"), today confirmed that Biogen Inc. (Nasdaq: BIIB) ("Biogen ...